X-ray screening identifies compounds that block a major coronavirus enzyme
A new screening study has shown that three natural compounds present in foods like green tea may be candidates for drugs that combat the coronavirus.
List view / Grid view
A new screening study has shown that three natural compounds present in foods like green tea may be candidates for drugs that combat the coronavirus.
In this episode, experts discuss how they use ELISA assays in their research as well as the specific benefits of this kind of immunoassay.
Are you using LC-MS in your drug development studies and looking to automate your sample prep workflow? Download our ebook to learn more.
7 September 2022 | By Sartorius
Watch this webinar to hear from Dr Yuansheng Yang as he introduces a CHO cell-based technology allowing simultaneous display and secretion of antibodies for accelerating the process of antibody development.
Application note: Quantifying T Cell response in 3D tumour spheroids using advanced flow cytometry workflows.
This publications review overviews advanced flow cytometry applications in infectious disease and immuno-oncology.
This guide highlights the four major stages of TPD, the challenges at each step and questions you should ask yourself.
Scientists have identified a molecule that can bind to a lethal subtype of the bacterial Shiga toxin, suppressing its deadly effects.
This whitepaper overviews how high throughput, multi-parametric analysis accelerates antibody discovery workflows.
Researchers from the US have identified several new small molecules that can induce mitophagy in leukaemia cells.
Researchers have identified a DNA-derived molecule that binds to and inhibits the function of CYP24 and shows promising antiproliferative activity.
NRG is developing a pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson's disease and motor neuron disease.
Scientists have synthesised a new molecule that could kill a broad spectrum of hard-to-treat cancers, including triple-negative breast cancer, by exploiting a weakness in cells not previously targeted by other drugs.
Here Bio-Rad presents the generation of specific anti-CAR T-cell antibodies to show how CAR T-cell analysis benefits from our modular antibody assembly technology using SpyTag-SpyCatcher protein ligation.
9 May 2022 | By PerkinElmer and C4
Looking for a way to address the undruggable proteins in the human body? Watch this free on-demand webinar where industry experts discuss strategies to accelerate TPD drug discovery efforts using high-throughput cell-based assays.